Patient-reported outcomes research pioneer, Ethan Basch, MD, MSc, FASCO will serve as Scientific Advisory Board Director to build health care technology company’s patient-reported outcomes (PRO) and RWE analytics platform.
North Miami, Florida — February 26, 2019 — Carevive, a health technology company that builds cancer care management and patient engagement solutions to improve patient quality of life and clinical outcomes, announced today that Ethan Basch, MD, MSc, FASCO, will serve as Scientific Advisory Board Director (SAB Director). Basch is a medical oncologist and distinguished professor in the UNC School of Medicine Division of Hematology/Oncology and a professor in the UNC Gillings School of Global Public Health. He also is director of UNC Lineberger’s cancer outcomes research program. He was also recently elected to the American Society of Clinical Oncology (ASCO) Board of Directors.
As SAB Director, Basch will work with Carevive to develop the strategic vision and plan for Carevive’s electronic patient-reported outcome (ePRO) product and real-world evidence registry & analytic platform. A key portion of his role will help define clinical best practices for real-world implementation of ePROs, a workflow within oncology clinics that has yet to be adopted routinely. Basch will also work with Carevive to assemble a Scientific Advisory Board to provide guidance on products and projects where scientific input is relevant.
“We are thrilled to have Ethan leading our Scientific Advisory Board,” said Madelyn Herzfeld, Carevive’s Co-Founder and Chief Executive Officer. “His research in electronic patient-reported outcomes has inspired cancer clinicians and researchers around the world to quantify and value the patient experience and intervene quickly when symptoms arise because doing so results in dramatic improvements in patients’ treatment outcomes. He will also be instrumental in developing a model on how real-world patient-reported outcomes can be used to better understand new oncology treatments seeking U.S. Food & Drug Administration (FDA) approval.”
Basch said, “PROs have been shown to improve clinical outcomes, reduce care utilization, and improve patient satisfaction, but have yet to be widely implemented in oncology practice. Moreover, the value of real-world PRO data in product development and evaluation is of rising interest to regulatory authorities. So, on both of these counts, there is a substantial opportunity at this moment for organizations that can implement ePRO in practice – both to improve care quality and to generate meaningful effectiveness data.”
Carevive’s recently released ePRO tool, Carevive PROmPt™, allows cancer patients to report their symptom remotely in between clinic visits so that providers can manage quickly and efficiently, prior to symptoms getting so severe that treatment would be compromised. Basch and the Scientific Advisory Board members will work with Carevive’s team and provide input on the strategic design of Carevive PROmPt™ to maximize impact on clinical and financial outcomes for cancer centers.
In a ground-breaking study presented at the 2017 ASCO Annual meeting, Basch and his colleagues found that cancer patients who routinely reported their symptoms to their cancer care providers using a web-based survey and nursing intervention experienced longer time on treatment, better survival outcomes, improved quality of life, and decreased ED visits and hospitalizations.
Carevive is a health technology company focusing on care management and patient engagement solutions to improve the quality of life and clinical outcomes of cancer patients. Our platform analyzes clinical and patient-reported data, and the latest clinical guidelines, to offer evidence-based recommendations to clinicians so they can improve patient outcomes from cancer treatment. Our health system customers often partner with us and life science companies to use our insights of the real-world cancer patient experience to inform the drug development process. Carevive has partnered with over 35 academic and community cancer programs and 8 oncology-focused life science companies. For more information, please visit www.carevive.com or follow us @carevive.